Peter Littlejohns1. Show Affiliations » 1. UK National Institute for Health and Clinical Excellence, London. Peter.littlejohns@nice.org.uk
Abstract
Entities: Chemical Disease
Mesh: See more » Antibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents/economicsAntineoplastic Agents/therapeutic useBiomedical ResearchBreast Neoplasms/drug therapyBreast Neoplasms/pathologyClinical Trials as TopicCost-Benefit AnalysisDrug CostsHumansNational Health ProgramsNeoplasm StagingResearch Support as TopicSurvival AnalysisTrastuzumabUnited Kingdom
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsTrastuzumab
Year: 2006 PMID: 16408378 DOI: 10.1016/s1470-2045(05)70533-7
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316